Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med

Novo Nordisk ($NVO) is humming along with its fast-growing GLP-1 drug Victoza. But it's also eyeing a follow-up to that once-daily med, touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that the drug slashed HbA1c levels and delivered significant weight loss in a new trial. More data is coming later this year. Report | Release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.